Skip to main content
ABSTRACT & COMMENTARY

Bendamustine-rituximab compared with R-CHOP or R-CVP for first-line treatment of indolent NHL

In an international, randomized, non-inferiority trial, bendamustine-rituximab proved comparable in overall response rate when compared with R-CHOP or R-CVP in the management of indolent NHL and mantle cell lymphoma. Progression free and overall survival comparisons remain to be determined. Notably, toxicity profiles were significantly different, with higher rates of reported nausea and vomiting with BR and neuropathy and alopecia with R-CHOP/R-CVP.